Clinical Trial Update: Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating safety and immunogenicity of oral tecovovirmat (TPOXX) given for 28 days in combination with the JYNNEOS smallpox vac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• JYNNEOS (Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN))
• TPOXX (tecovirimat monohydrate)

Snippet

Sponsor: SIGA Technologies | Conditions: Smallpox | Phase 2 | Status: ACTIVE_NOT_RECRUITING